Efficacy and safety of neridronate in paediatric type I complex regional pain syndrome: a multicentre experience
Authors' conclusion
Our data suggest that in children as in adults with CRPS I, neridronate may represent an effective and safe treatment option, particularly in those who do not respond to other pain treatments.
Study context
- Population
- Children with CRPS I (Budapest criteria) not responding to previous pharmacological and physical therapy, three paediatric rheumatology centresmean age 10.4 years
- Participants
- 5 children
- Outcome
- Pain (VAS), average
- Follow-up
- Pre- vs post-treatment
Methodological detailsmulticentre, retrospective data collection
- Multicentre
- Retrospective data collection
Main finding
As reported in the abstract
Patients reporting significant improvement in pain, recovery of physical function and reduced need for pain medications
4 of 5
Average VAS pre-treatment
9.6
Average VAS post-treatment
2.6
Observational data: associations, not effects.
Further findings
Bone oedema on MRI (present in all before treatment)
- Bone oedema disappeared
- 3
Safety
- Mild flu-like symptoms (only adverse effect)
- 1
- Well-tolerated
Original publication
Efficacy and safety of neridronate in paediatric type I complex regional pain syndrome: a multicentre experience. Clin Exp Rheumatol. Published 8 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →